A new publication related to sermorelin, a growth hormone-releasing hormone (GHRH) analog, was indexed on October 1, 2026. The paper, titled "Growth hormone-releasing hormone antagonists protect endothelial corneal cells against lipopolysaccharides-induced inflammation," appeared in the journal Experimental Eye Research.
Sermorelin remains classified as an unapproved research compound. The publication concerns GHRH antagonists, which act on the same signaling pathway associated with sermorelin, a GHRH analog.
This entry reflects only the existence and details of the publication as listed in the source record. No findings, data, or conclusions from the study are described here beyond the title and journal of record. Readers seeking to understand the specific content, methodology, or results of this study should consult the original publication directly.
As with all research-stage compounds, information about GHRH-related science should be evaluated in the context of its current regulatory status and the specific study population and design, none of which are detailed in this brief. This item is intended solely to note that new peer-reviewed literature referencing GHRH pathway modulation has entered the public record.
For more background on sermorelin, readers can consult the compound overview.